(a)
| Microarray study (N = 10) | PCR study (N = 33) | |||||
|---|---|---|---|---|---|---|
| Variable | Normal or mild (N = 7) | Advanced CAV (N = 3) | P-value | Normal or mild (N = 28) | Advanced CAV (N = 5) | P-value |
| Time after HTx (days) | 232 (81–298) | 42 (41–96) | .067 | 81 (7–171) | 55 (41–167) | .643 |
| Follow-up time (years) | 5.3 (4.8–5.8) | 5.6 (5.4–5.7) | .138 | 5.5 (4.6–6.2) | 5.7 (5.1–5.8) | .315 |
| Male gender recipient | 6 (85.7%) | 3 (100%) | 1 | 21 (75.0%) | 4 (80%) | 1 |
| Male gender donor | 6 (85.7%) | 2 (66.7%) | 1 | 20 (71.4%) | 3 (60%) | .627 |
| Caucasian recipient | 5 (71.4%) | 3 (100%) | .585 | 21 (63.6%) | 5 (100%) | .903 |
| Caucasian donor | 7 (100%) | 1 (33%) | .67 | 17 (60.7%) | 2 (40%) | .685 |
| Recipient age | 55.6 ± 8.2 | 48.5 ± 13.5 | .383 | 52.6 ± 105 | 61.4 ± 8 | .173 |
| Donor age | 31.7 ± 11.7 | 44.1 ± 7.9 | .183 | 32.8 ± 13.0 | 41.5 ± 13.7 | .226 |
| ICM recipient | 5 (71.4%) | 1 (33.3%) | .11 | 14 (50%) | 4 (80%) | .267 |
| LVAD | 3 (42.9%) | 2 (66.7%) | 1 | 7 (21.2%) | 2 (40%) | .597 |
| Recipient CMV (+) | 2 (28.6%) | 0 (0.00%) | .53 | 11 (33.3%) | 2 (40%) | .347 |
| Donor CMV (+) | 3 (42.9%) | 2 (40.0%) | .7 | 14 (50%) | 4 (80%) | .445 |
| Ischemic time (Min) | 188.7 ± 65.1 | 138 ± 36.6 | .229 | 183.9 ± 49.2 | 156 ± 7 | .208 |
| Daclizumab induction | 7 (100%) | 3 (100%) | — | 24 (85.7%) | 4 (80%) | |
| Prednisone | 7 (100%) | 3 (100%) | — | 28 (100%) | 5 (100%) | — |
| Prednisone dose | 8.71 ± 7.8 | 13.3 ± 2.9 | .296 | 16.3 ± 10.2 | 13.0 ± 4.5 | .359 |
| Maintenance Regimen | 1 | .295 | ||||
| Cyclosporine | 6 (85.7%) | 3 (100%) | 24 (85.7%) | 4 (80%) | ||
| Tacrolimus | 1 (14.3%) | 0 (0.0%) | 3 (10.7%) | 0 (0%) | ||
| Sirolimus | 0 (0.0%) | 0 (0.0%) | 1 (3.6%) | 1 (20%) | ||
| Cyclosporine levels (ng/ml) | 437.0 ± 489 | 225.3 ± 26 | .655 | 312.5 ± 226 | 229.25 ± 22 | .212 |
| Tacrolimus levels (ng/ml) | 8.5 ± 0.2 | — | — | 11.7 ± 2.5 | — | — |
| Sirolimus levels (ng/ml) | — | — | — | 6 | 5.6 | — |
| Mycophenolate | 6 (85.7%) | 3 (100%) | 1 | 24 (85.7%) | 5 (100%) | 1 |
| Azathioprine | 0 (0.0%) | 0 (0.0%) | — | 0 (0.0%) | 0 (0.0%) | — |
| Simvastatin | 1 (14%) | 1 (33%) | 1.00 | 2 (7%) | 0 (0%) | 1.00 |
| Cellular rejection (ISHLT) | .161 | .78 | ||||
| 0R | 4 (57.1%) | 2 (66.7%) | 24 (85.7%) | 4 (80%) | ||
| 1R | 3 (42.9%) | 0 (0.0%) | 4 (14.3%) | 1 (20%) | ||
| 2R | 0 (0.0%) | 1 (33.3%) | 0 (0%) | 0 (0%) | ||
| New episodes of rejection | ||||||
| 1R/1B | 0 (0–1) | 0 (0–0) | .513 | 0 (0–4) | 0 (0–3) | .688 |
| 2R | 1 (0–1) | 1 (0–1) | .789 | 0 (0–2) | 0 (0–1) | .375 |
| 2R/3A | 0 (0–1) | 0 (0–0) | .513 | 0 (0–2) | 0 (0–3) | .898 |
HTx: heart transplant; LVAD: left ventricular assist device; RT-PCR: real-time polymerase chain reaction.